Clinical Trials for Mesothelioma Patients—Sorafenib, Pemetrexed, and Cisplatin: Outcome Measures

Read about the outcome measures for a current clinical trial about the use of Sorafenib, Pemetrexed, and Cisplatin for patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only

Primary Outcome Measures:

• Maximum tolerated dose of sorafenib tosylate [ Designated as safety issue: Yes ]

• Toxicity as assessed by NCI CTCAE v3.0 [ Designated as safety issue: Yes ]

• Disease response as assessed by RECIST criteria [ Designated as safety issue: No ]

Estimated Enrollment: 12

Study Start Date: May 2008

Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.